Skip to main content
IRLAB Therapeutics logo

IRLAB Therapeutics — Investor Relations & Filings

Ticker · IRLAB ISIN · SE0012675361 LEI · 549300JAT34LHEI0DH60 ST Manufacturing
Open in API
Filings indexed 156 across all filing types
Latest filing 2025-07-02 Capital/Financing Update
Country SE Sweden
Listing ST IRLAB

About IRLAB Therapeutics

https://irlab.se/

IRLAB Therapeutics is a research and development company that discovers and develops novel treatments for neurodegenerative diseases, with a primary focus on Parkinson's disease and other central nervous system (CNS) disorders. The company's research originates from Nobel Prize-winning science and is driven by its proprietary Integrative Screening Process (ISP) platform. This systems pharmacology-based discovery engine utilizes an extensive database to generate a pipeline of drug candidates. The company's portfolio includes clinical-stage assets such as Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), which is being developed to reduce falls and improve balance in patients with Parkinson's disease.

Recent filings

Filing Released Lang Actions
IRLAB offentliggör informationsdokument i samband med företrädesemissionen
Capital/Financing Update Classification · 98% confidence The document is a press release from IRLAB Therapeutics AB announcing the publication of an 'Informationsdokument' (Information Document) related to a rights issue ('företrädesemission'). The text explicitly mentions that this document was prepared in accordance with the EU Prospectus Regulation (Article 1.4 db) and Annex IX, and has been registered with the Swedish Financial Supervisory Authority (Finansinspektionen). This type of document, which provides detailed information for a public offering of securities (a rights issue), is fundamentally related to capital raising and financing activities. While it is an announcement, the core subject is the creation and availability of a formal document detailing a capital change/offering. This aligns best with the 'Capital/Financing Update' (CAP) category, as it details the terms and timeline of a significant financing event (a rights issue of up to 136 MSEK). It is not a general regulatory filing (RNS) because it is highly specific to a capital action, nor is it a standard prospectus, but rather an 'Information Document' required for such an offering. Given the focus on the rights issue and the associated document, CAP is the most appropriate classification.
2025-07-02 Swedish
IRLAB publishes information document in connection with the rights issue
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that IRLAB Therapeutics AB has prepared an 'information document' in connection with a rights issue of shares. It explicitly states that the Information Document is prepared in accordance with the Prospectus Regulation and has been registered with the Swedish Financial Supervisory Authority. The core subject is a capital raising/financing activity (Rights Issue) and the associated disclosure document. This aligns best with the 'Capital/Financing Update' (CAP) category, as it details the terms and timeline of the financing event. Although it mentions the 'Information Document' (which is similar to a prospectus), the document itself is the announcement of this action, not the full financial report (10-K) or a general regulatory filing (RNS). Since the primary focus is the capital structure change, CAP is the most specific fit over RNS.
2025-07-02 English
The Board of Directors of IRLAB has resolved on an 85 per cent secured rights issue of approximately SEK 136 million and receives extended debt financing of SEK 30 million
Capital/Financing Update Classification · 98% confidence The document is a press release announcing that the Board of Directors has resolved on an 85% secured rights issue of approximately SEK 136 million and has extended debt financing. The core subject is a significant capital raising activity involving the issuance of new shares via subscription rights. This directly corresponds to the definition of a Capital/Financing Update (CAP). Although it mentions an 'information document' will be published later, the document itself is the primary announcement detailing the terms, amounts, and shareholder implications of the financing, making CAP the most accurate classification over RPA or RNS.
2025-06-24 English
IRLAB genomför en till 85 procent garanterad företrädesemission om cirka 136 MSEK och erhåller förlängd lånefinansiering om 30 MSEK
Capital/Financing Update Classification · 98% confidence The document is a press release announcing a rights issue ('företrädesemission') of approximately 136 MSEK and an extension of loan financing. This activity directly relates to the company's fundraising, financing activities, and capital structure changes. According to the definitions, this clearly falls under 'Capital/Financing Update' (Code: CAP). The document is an announcement, but the core subject is the financing event itself, not just the announcement of a report (which would be RPA/RNS). The length (25,237 chars) suggests it is the primary document detailing the transaction, not just a brief notice.
2025-06-24 Swedish
Kommuniké från årsstämman 2025 i IRLAB Therapeutics AB
AGM Information Classification · 99% confidence The document is explicitly titled "Kommuniké från årsstämman 2025 i IRLAB Therapeutics AB" (Communiqué from the Annual General Meeting 2025 in IRLAB Therapeutics AB). It details the key resolutions passed during the meeting, such as the approval of financial statements, dividend disposition, election of board members and auditor, and authorizations for new share issues. These are the typical contents of an AGM resolution summary or minutes. Since it is a summary/communiqué of the meeting outcomes, the most appropriate classification is AGM-R (AGM Information). It is not a full Annual Report (10-K) or a proxy statement (PSI), but a direct report on the meeting's decisions.
2025-06-11 Swedish
Report from the Annual General Meeting 2025 of IRLAB Therapeutics AB
AGM Information Classification · 100% confidence The document explicitly states it is the "Report from the Annual General Meeting 2025 of IRLAB Therapeutics AB" and details the resolutions passed during that meeting, such as the adoption of financial statements, election of board members, and remuneration decisions. This content directly corresponds to the materials presented or summarized from an Annual General Meeting. Therefore, the classification is AGM-R (AGM Information). The document length is substantial (8871 chars), indicating it is the report/summary itself, not just a brief announcement of publication (which would suggest RPA or RNS).
2025-06-11 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.